Breast Cancer News
In this section, access cutting-edge breast cancer news on treatment updates, emerging therapies, study results and other medical and quality-of-life issues important to you.
Learn about results from two studies that show adding bevacizumab (Avastin) to chemotherapy before surgery improves the rate of pathologic complete response in HER2 negative breast cancer that has not traveled to other parts of the body.
NEW YORK (Reuters Health) - Some elderly women with early-stage breast cancer may be getting extra treatment that does them little good but comes with costs and possible side effects, according to a new study.
Learn how new research has prompted the American Society of Clinical Onclolgy (ASCO) to recommend that doctors offer palliative care alongside standard medical treatment for people diagnosed with metastatic cancers.
NEW YORK (Reuters Health) - Women on chemotherapy for breast cancer may have tiny memory and thinking impairments compared with cancer-free women more than 20 years after their treatment, Dutch researchers have found.
(Reuters) - AstraZeneca Plc is selling breast cancer drug Arimidex directly to U.S. patients, offering an option for people who want to pay for the brand instead of generic versions.
Women 65 and older are less likely to survive breast cancer than their younger counterparts, two recent studies suggest.
NEW YORK (Reuters Health) - Mutations in genes that fix mismatched DNA may put people at extra risk for breast cancer and pancreatic cancer, in addition to their well-known ties to colon and endometrial cancers, a new report suggests.
NEW YORK (Reuters Health) - About two-thirds of women diagnosed with early stage breast cancer want to take part in making decisions about their treatment, according to a new survey of patients from five different countries.
NEW YORK (Reuters Health) - Breast cancer is often considered more deadly among younger women, but a new study shows older women are actually more likely to die of the disease.
WASHINGTON (Reuters) - Reviewers from the U.S. Food and Drug Administration said on Monday that they were not sure whether Amgen Inc's Xgeva bone drug should be approved for a wider use of delaying the spread of cancer to the bone.